Ross Levine

Dr. Levine is the Chief of the Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program at Memorial Sloan Kettering (MSK), an attending physician in the Leukemia Service, Department of Medicine, the Laurence Joseph Dineen Chair in Leukemia Research, and a Professor of Medicine at Weill Cornell Medical College.

His lab focuses on elucidating the genetic basis of myeloid malignancies, and in turn to improve outcomes for patients with these disorders. His primary research interests include the role of JAK-STAT signaling in malignant transformation, and the effects of mutations in epigenetic modifiers in clonal hematopoiesis, MPN, and AML. Moreover, as a physician scientist, his lab has a specific interest in translating this knowledge back to the clinic, and actively participating in the preclinical and clinical evaluation of targeted therapies for leukemia patients.

Dr. Levine has been honored with the Dameshek Prize from the American Society of Hematology, a Scholar Award from the Leukemia and Lymphoma Society, the Boyer Award for Clinical Investigation from Memorial Sloan Kettering Cancer Center, and a NCI Outstanding Investigator R35 Award. In 2011, he was elected to the American Society of Clinical Investigation, and in 2018, to the Association of American Physicians. He serves on the Supervisory Board of Qiagen, and on the Scientific Advisory Board of C4 Therapeutics, Isoplexis, and Mana Therapeutics. Earlier, he was on the Scientific Advisory Board of Loxo Oncology.

Dr. Levine served as a Resident in Internal Medicine at Massachusetts General Hospital and as a Hematology-Oncology Fellow at Dana-Farber Cancer Institute. Dr. Levine earned his AB from Harvard College, and a Member – Scientific Advisory Board from Johns Hopkins.